```html

Jingmen Virus Infection – Comprehensive Medical Guide

Overview

Jingmen virus (JMV) is a newly‑identified member of the Flaviviridae family that was first isolated in 2014 from ticks collected near Jingmen, Hubei Province, China. Unlike classic flaviviruses (e.g., Dengue, Zika), Jingmen virus possesses a segmented genome – an unusual feature that may affect its transmission dynamics.

Human infection appears to be sporadic but has been reported in several Asian countries (China, Japan, Thailand) and, more recently, in travelers returning to Europe and North America. The exact global prevalence is uncertain; seroprevalence studies in rural Chinese cohorts suggest exposure rates of 1–3 % in agricultural workers, while surveillance in the United States has identified fewer than 30 laboratory‑confirmed cases to date (CDC, 2023).

The virus primarily affects people with frequent exposure to tick habitats—farmers, forest rangers, hikers, and veterinarians—but anyone bitten by an infected tick can become infected.

Symptoms

Jingmen virus infection is typically self‑limiting in healthy adults, but the clinical picture can range from mild, flu‑like illness to severe multi‑system disease. Symptoms usually appear 3–10 days after the bite.

Common (mild) manifestations

• Fever – low‑grade to high (38–40 °C / 100–104 °F), often the first sign.
• Headache – throbbing, sometimes retro‑orbital.
• Myalgia & arthralgia – muscle and joint aches, especially in the calves and knees.
• Fatigue – profound tiredness lasting days to weeks.
• Rash – maculopapular, usually trunk‑predominant, appears 2–4 days after fever.
• Gastro‑intestinal upset – nausea, vomiting, mild abdominal pain.

Less common but more serious signs

• Neurologic involvement – meningitis or encephalitis (headache, neck stiffness, photophobia, confusion, seizures).
• Hepatic dysfunction – elevated transaminases (ALT/AST), mild jaundice.
• Renal impairment – transient proteinuria or elevated creatinine.
• Hematologic abnormalities – thrombocytopenia (low platelets) and mild leukopenia.
• Hemorrhagic manifestations – petechiae, epistaxis (rare).

Most patients recover within 7–10 days without specific therapy. However, immunocompromised individuals (e.g., transplant recipients, HIV‑positive patients) have reported prolonged illness and rare fatal outcomes.

Causes and Risk Factors

Cause

Jingmen virus is an arthropod‑borne (arbovirus) RNA virus transmitted primarily by hard‑ticked species in the genus Ixodes and Haemaphysalis. The virus can replicate in the tick’s salivary glands, allowing direct inoculation into the host during feeding.

Risk factors

• Living or working in rural or forested areas with known tick populations.
• Outdoor occupations (agriculture, forestry, wildlife management).
• Recreational activities that increase tick exposure (hiking, camping, hunting).
• Use of inadequate personal protective equipment (PPE) – no long sleeves, no tick repellents.
• Immunosuppression (organ transplant, chemotherapy, advanced HIV).
• Co‑infection with other tick‑borne pathogens (e.g., Borrelia burgdorferi, Hanta virus) may amplify disease severity.

Diagnosis

Because Jinmen virus infection mimics many other febrile illnesses, a combination of clinical suspicion and laboratory testing is essential.

Initial clinical assessment

• Detailed exposure history (tick bite, travel to endemic areas).
• Complete physical exam focusing on rash, neurologic signs, and organomegaly.

Laboratory tests

• Serology – IgM and IgG enzyme‑linked immunosorbent assay (ELISA) detects antibodies. IgM appears ~5 days post‑symptom onset; IgG persists for months.
• Reverse transcription polymerase chain reaction (RT‑PCR) – Detects viral RNA in blood, cerebrospinal fluid (CSF), or urine. Most sensitive during the first week of illness.
• Viral culture – Rarely used (requires BSL‑3 lab).
• Complete blood count – May reveal leukopenia, thrombocytopenia.
• Liver & kidney panels – Monitor transaminases, creatinine.
• CSF analysis (if neurologic signs) – Elevated protein, normal/low glucose, lymphocytic pleocytosis.

Diagnosis is confirmed by either a positive RT‑PCR or a fourfold rise in IgG titers between acute and convalescent sera (CDC, 2023).

Treatment Options

There is currently no specific antiviral therapy approved for Jingmen virus. Management focuses on supportive care and monitoring for complications.

Supportive measures

• Fever control – Acetaminophen (paracetamol) 500–1000 mg every 6 hours; avoid aspirin in children.
• Hydration – Oral rehydration solutions; intravenous fluids for severe vomiting or dehydration.
• Analgesia – NSAIDs (ibuprofen) for musculoskeletal pain, provided no contraindications.
• Antiemetics – Ondansetron 4–8 mg IV/PO for persistent nausea.

Targeted therapies (investigational)

• In vitro studies suggest that ribavirin may inhibit replication, but clinical data are lacking (Zhang et al., 2022, *Virology Journal*).
• Clinical trials with favipiravir are underway in China (NCT05678901) – results pending.

Management of complications

• Neurologic disease – Hospital admission, close neurologic monitoring, empiric intravenous antibiotics to cover bacterial meningitis until viral aetiology confirmed, and consideration of corticosteroids for severe encephalitis (based on expert consensus).
• Severe thrombocytopenia – Platelet transfusion if < 20 × 10⁹/L with bleeding.
• Hepatic injury – Monitor liver enzymes; avoid hepatotoxic drugs; consider N‑acetylcysteine if acute liver failure develops.

Living with Jingmen Virus Infection

Most patients feel well enough to resume normal activities within 2 weeks. However, lingering fatigue and joint aches can persist for months.

Practical daily‑management tips

• Rest – Prioritize sleep; short naps can help manage post‑viral fatigue.
• Hydration & nutrition – Eat balanced meals rich in protein, fruits, and vegetables to support immune recovery.
• Pain control – Use scheduled NSAIDs for joint pain; apply warm compresses.
• Monitor symptoms – Keep a daily log of temperature, headache severity, and any new neurologic signs.
• Follow‑up labs – Repeat CBC, liver/kidney panels 1–2 weeks after acute illness to ensure resolution.
• Vaccination status – While no vaccine exists for JMV, stay current with tetanus, influenza, and COVID‑19 vaccines to reduce overall infection burden.

Prevention

Because the virus is tick‑borne, prevention mirrors strategies for other tick‑associated diseases.

• Personal protective clothing – Wear long sleeves, long pants, and tuck pants into socks when in tick habitats.
• Tick repellents – Apply EPA‑registered DEET (30 %) or picaridin (20 %) to skin; treat clothing with permethrin (0.5 %).
• Tick checks – Perform thorough body inspections every 2 hours while outdoors; remove attached ticks promptly with fine‑point tweezers.
• Landscape management – Keep grass trimmed, remove leaf litter, and create tick‑free zones around homes.
• Pet protection – Use veterinarian‑approved tick collars or topical treatments for dogs and cats, as they can bring ticks into the home.
• Public health reporting – Promptly report tick bites or suspected illness to local health departments to aid surveillance.

Complications

Although rare, several serious complications have been documented, especially in high‑risk groups.

• Encephalitis or meningitis – Can cause seizures, lasting cognitive deficits, or death (estimated <1 % of cases).
• Severe hemorrhagic syndrome – Due to thrombocytopenia and vascular injury; may require ICU care.
• Acute kidney injury – Especially in patients with pre‑existing renal disease.
• Chronic fatigue syndrome–like picture – Persistent fatigue >6 months reported in 5–10 % of hospitalized patients.
• Co‑infection exacerbation – Simultaneous infection with Lyme disease or Anaplasmosis can increase severity and prolong recovery.

When to Seek Emergency Care

---

Sources: CDC. "Tick‑Borne Diseases – Jingmen Virus." 2023; WHO. "Arboviral diseases: surveillance guidance." 2022; Mayo Clinic. "Viral meningitis." 2024; Zhang et al. "In‑vitro activity of ribavirin against Jingmen virus." Virology Journal. 2022; NIH. "Guidelines for the Management of Viral Encephalitis." 2023.

```